Indication
Programmed Cell Death 1 Ligand 2 (PDL2)
1 clinical trial
3 products
Clinical trial
Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-06
Product
Sacituzumab tirumotecanProduct
PembrolizumabProduct
Carboplatin